Jpmorgan Chase & CO Hcw Biologics Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding HCWB
# of Institutions
17Shares Held
1.16MCall Options Held
0Put Options Held
0-
Avantax Planning Partners, Inc.280KShares$357,8120.01% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$234,5710.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL181KShares$231,4360.0% of portfolio
-
Cresset Asset Management, LLC Chicago, IL132KShares$168,9470.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX84.7KShares$108,4160.0% of portfolio
About HCW Biologics Inc.
- Ticker HCWB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,833,100
- Market Cap $45.9M
- Description
- HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...